Shopping Cart
Remove All
Your shopping cart is currently empty
NU6300 is an inhibitor of the first covalent ATP-competitive CDK2.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $999 | - | In Stock |
| Description | NU6300 is an inhibitor of the first covalent ATP-competitive CDK2. |
| Targets&IC50 | CDK2:0.16 μM |
| In vitro | NU6300 blocks the inhibitor binding site. The effect was time-dependent and relatively slow, with less than 50% reduction of the apparent binding capacity in 20 hr. NU6300 is a covalent CDK2 inhibitor that illustrates the potential of using vinyl sulfones to mediate irreversible inhibition. |
| Synonyms | NU 6300 |
| Molecular Weight | 413.49 |
| Formula | C20H23N5O3S |
| Cas No. | 2070015-09-5 |
| Smiles | C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1 |
| Relative Density. | 1.344 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (193.48 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.98 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.